Fig. 5: Tetravalent anti-mCD27 generates superior anti-tumor responses compared to its bivalent counterpart.
From: Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy
A Percentage survival to the humane endpoint of Balb/c mice inoculated with BCL1 lymphoma and treated with the indicated antibodies on day 4. Data shown are from 10 mice across 2 independent experiments (n = 10 mice per group). B Individual tumor growth curves of Balb/c mice inoculated with CT26 colon carcinoma and treated with the indicated antibodies on days 11, 13, 16, 18. Data shown are from 9 mice (Isotype mIgG1) or 10 mice (anti-mCD27 mIgG1 and tetra anti-mCD27 mIgG1) across 2 independent experiments, with non-responders shown in blue and responders shown in purple. C Summary of tumor growth data from responding and isotype control mice shown in (B), calculated as the group mean AUC of Isotype mIgG1 (n = 9), anti-mCD27 mIgG1 (n = 6), or tetra anti-mCD27 mIgG1 (n = 5), with error bars indicating SD. D Percentage survival of CT26-bearing mice in (B) to the humane endpoint. Statistical significance was determined by Log-rank (Mantel–Cox) test (A, D), two-way ANOVA (B), or one-way ANOVA (C), with significance values indicated in the figure. For analysis of statistical significance by ANOVA, Tukey’s post-hoc test was used for multiple comparisons. Source data are provided as a Source data file.
